The study examined 215 individuals with prediabetes, each of whom had at least five years of follow-up. The median observation period was seven years. The investigators focused on two measures: lipoprotein(a), abbreviated Lp(a), and the triglyceride-glucose index, or TyG, which the researchers describe as a surrogate marker of insulin resistance.

Receiver operating characteristic curve analysis was used to identify optimal thresholds for the two measures. Participants were then divided into four groups based on whether they had high or low Lp(a) and high or low TyG. The high-Lp(a)/low-TyG group served as the reference group.

Among participants who developed type 2 diabetes, the median TyG index was 9.0, with an interquartile range of 8.6 to 9.4. Among those who did not develop diabetes, the median was 8.6, with an interquartile range of 8.3 to 9.0. The difference was statistically significant at p less than 0.01.

The pattern for Lp(a) ran in the opposite direction: median Lp(a) was 12.0, with an interquartile range of 8.0 to 30.5, among participants who developed diabetes, compared with 19.0, with an interquartile range of 9.0 to 51.0, among those who did not; this difference had a p value below 0.05. In Cox regression analysis, the low-Lp(a)/high-TyG group had the highest observed risk of incident type 2 diabetes relative to the reference group. Its hazard ratio was 2.45, with a 95% confidence interval of 1.08 to 5.57, and p less than 0.05.

The other two groups did not show statistically significant associations. The low-Lp(a)/low-TyG group had a hazard ratio of 0.95, with a 95% confidence interval of 0.30 to 2.95 and p equal to 0.93, while the high-Lp(a)/high-TyG group had a hazard ratio of 1.22, with a 95% confidence interval of 0.70 to 2.11 and p equal to 0.48. High-sensitivity C-reactive protein, or Hs-CRP, was independently associated with incident type 2 diabetes in the regression analysis.

Its hazard ratio was 1.26, with a 95% confidence interval of 1.06 to 1.50, and p below 0.01. This result concerns an association within the study model; the supplied results do not establish that Hs-CRP causes diabetes or that it improves prediction beyond the other measures in practice. Together, the observations suggest that the combination of low Lp(a) and high TyG may identify a group with elevated risk among people with prediabetes.

The result is not evidence that either biomarker combination causes diabetes, nor does it show that the measures can predict an individual outcome with certainty. The study was retrospective, included a modest sample of 215 people with prediabetes, and reported that participants had at least five years of follow-up. The investigators describe the findings as hypothesis-generating and call for validation in larger studies to determine their potential value for risk stratification.

The confidence intervals, including the 95% interval of 1.08 to 5.57 for the low-Lp(a)/high-TyG association, indicate uncertainty around the estimated hazard ratio. Accordingly, the findings support further investigation of the combined signal, but the size and usefulness of that signal outside the studied population remain uncertain. The study was reported in the Journal of Translational Medicine as an open-access research article, with the publisher’s verified reference supplied separately.

Subject of Research: Association of lipoprotein(a) and triglyceride-glucose index with type 2 diabetes incidence in people with prediabetes

Article Title: Combined predictive value of lipoprotein(a) and triglyceride-glucose index for diabetes risk in a prediabetic population

Article References: Bosco, G., Guillerme, S., Bittar, R., Perregaux, J.-F., Redheuil, A., Ponnajah, M., De Francesco, E. M., Malaguarnera, R., Beaudeux, J. L., Le Goff, W., Scicali, R., Piro, S., & Gallo, A. (2026). Combined predictive value of lipoprotein(a) and triglyceride-glucose index for diabetes risk in a prediabetic population. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09075-0

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09075-0

Keywords: prediabetes, type 2 diabetes, lipoprotein(a), triglyceride-glucose index, TyG index, insulin resistance, diabetes risk, Cox regression, Hs-CRP, cohort study, Combined, predictive

Calcific aortic stenosis is a progressive disorder in which the aortic valve leaflets thicken, accumulate fibrous tissue and become mineralized. Mechanical stress concentrated on the endothelial surface of the leaflets can disrupt the barrier and permit apoB-containing lipoproteins to enter and accumulate in valve tissue. The process is active biological remodeling rather than passive degenerative wear: endothelial injury, inflammation, extracellular-matrix changes, fibrosis and osteogenic signaling can begin decades before clinically detectable narrowing emerges. Once severe symptomatic stenosis develops, surgical or transcatheter aortic valve replacement remains the intervention capable of improving long-term prognosis. No pharmacological treatment has been proven to prevent calcific aortic stenosis or reliably slow hemodynamic worsening after lesions have formed.

Lp(a) is a genetically regulated lipoprotein with an LDL-like core containing apolipoprotein B-100, covalently linked to apolipoprotein(a), or apo(a). Variations in the LPA gene and the number of repeated kringle IV type 2 domains in apo(a) produce wide differences in circulating concentrations among individuals and populations. Smaller apo(a) isoforms are generally associated with higher Lp(a) levels. Approximately one-fifth of the global population exceeds commonly accepted high-risk thresholds, although the distribution differs markedly by ancestry: average concentrations are highest among Black populations, intermediate among Hispanic and South Asian groups and lowest among East Asian and White populations. Age, dietary habits and routine lifestyle modifications have comparatively little influence on the largely genetically determined concentration, although chronic kidney disease, inflammatory disorders, hepatic dysfunction and hormonal fluctuations can alter measurements in some subgroups.

Measurement itself requires care. Mass assays and molar assays do not yield directly interchangeable results because particle mass depends on apo(a) isoform size, and conversion factors vary among laboratories and platforms. The review notes that contemporary lipid-management guidance recommends a one-time Lp(a) test for adults, but Lp(a) is not presently a stand-alone diagnostic biomarker for calcific aortic stenosis, and no validated algorithm based on it dictates the timing of echocardiographic surveillance or valve replacement. In patients with the disorder, the measurement may be particularly informative in people with premature valve calcification, a family history of calcific aortic stenosis or premature atherosclerotic cardiovascular disease, unexpectedly rapid stenosis progression, or residual cardiovascular risk despite well-controlled LDL cholesterol. Conventional management of modifiable cardiovascular risks remains necessary because lifestyle and LDL-lowering strategies cannot substantially reduce genetically determined Lp(a).

The strongest proposed mechanism begins with oxidized phospholipids. Lp(a) is the primary carrier of circulating oxidized phospholipids in human plasma, and these molecules can activate valvular endothelial cells, recruit monocytes, stimulate inflammatory cytokine secretion and promote proliferative signaling in valve interstitial cells. Among patients with mild-to-moderate calcific aortic stenosis, higher Lp(a) and oxidized-phospholipid apoB levels have been associated with steeper increases in peak aortic jet velocity and greater risks of aortic valve replacement or cardiac mortality. Imaging studies have also found greater fluorine-18 sodium fluoride uptake, a marker of active microcalcification, among patients with elevated Lp(a). Cell experiments find that Lp(a) drives osteogenic transformation of human valve interstitial cells, while neutralizing oxidized phospholipids attenuates mineralization. These results support a pathway connecting systemic particles to local disease, but oxidized phospholipids also circulate on other apoB-containing lipoproteins and can be generated within diseased valves, leaving the relative contributions unresolved.

A second pathway involves autotaxin, an enzyme enriched in circulating Lp(a) that converts lysophosphatidylcholine into lysophosphatidic acid. Autotaxin can also be synthesized locally by valve interstitial cells. In explanted calcified human valves, autotaxin colocalizes spatially with apo(a) and oxidized-phospholipid deposits. Experimental studies indicate that lysophosphatidic acid activates nuclear factor-kappa B, interleukin-6 and bone morphogenetic protein signaling, amplifying inflammatory responses and promoting hydroxyapatite crystal deposition within valve tissue. Autotaxin inhibition has attenuated valve calcification in preclinical work, but these findings remain predominantly experimental and do not establish a human clinical benefit. Autotaxin and lysophosphatidic acid are not exclusive to Lp(a), so the pathway is better understood as part of a broader lipid-inflammatory network than as a uniquely Lp(a)-specific mechanism. The central model nevertheless links Lp(a) retention, oxidized-phospholipid delivery, autotaxin-lysophosphatidic acid signaling and osteogenic reprogramming of valve interstitial cells.

The clinical evidence is strongest for disease initiation rather than progression of established severe stenosis. LPA variants that raise Lp(a), including rs10455872 and rs3798220, have been associated with aortic valve calcification and incident obstructive stenosis, while Mendelian randomization studies and prospective cohorts support a population-level causal relationship. Because germline variants predate disease onset, these analyses are less vulnerable to reverse causation than ordinary observational associations. A 2024 individual-participant meta-analysis pooling five longitudinal cohorts reported that participants in the highest Lp(a) tertile had 41% faster progression of peak aortic jet velocity and 57% steeper increases in mean transvalvular gradient than those in the lowest tertile. Post-hoc findings from the ASTRONOMER trial suggest that excess risk associated with high Lp(a) and oxidized phospholipids is more pronounced in younger adults. The relative contribution of Lp(a) may be diluted in older patients with extensive fibrosis, macrocalcification, chronic kidney disease, hypertension and other comorbidities.

Those stage-dependent findings have not been uniform. One long-term population cohort found that Lp(a) predicted the onset of aortic valve calcium but not calcium-score progression among people who already had lesions. Differences in assay platforms, risk thresholds, baseline stenosis severity, imaging endpoints, participant ages and follow-up durations complicate comparisons across studies. The review therefore grades the evidence as strong for incident valve calcification and development of clinical aortic stenosis, moderate for hemodynamic progression and the need for valve replacement, weak and heterogeneous for progression of established calcification, and limited for mortality. This grading is a qualitative assessment of consistency and evidence quality, not a quantified effect size. The review searched PubMed and MEDLINE through 25 July 2026 and prioritized landmark randomized trials, prospective cohorts, Mendelian randomization studies and recent meta-analyses, but it did not use a preregistered protocol or formal systematic-review methods. Its synthesis is therefore a narrative assessment rather than a comprehensive quantitative estimate of every association.

Existing lipid-lowering trials illustrate the difficulty of translating pathway biology into valve outcomes. The SALTIRE, SEAS and ASTRONOMER randomized trials failed to slow progression of established calcific aortic stenosis with statin-centered treatment, although lipid pathways may participate during the earlier priming phase. PCSK9 inhibitors produce much larger reductions in LDL cholesterol and typically lower Lp(a) by approximately 20% to 30%. An exploratory FOURIER analysis linked baseline Lp(a) with incident aortic stenosis and produced a preliminary risk-reduction signal after the first treatment year, but the analysis was not prospectively designed around valve endpoints, had few events and changed both Lp(a) and LDL cholesterol. It therefore cannot establish that Lp(a) lowering modifies stenosis. Lipoprotein apheresis can reduce Lp(a) acutely by roughly 60% to 75%, but concentrations rebound rapidly between sessions, the intervention requires substantial resources, and robust evidence that it slows valve disease is absent.

More selective therapies have achieved much larger biomarker reductions without yet proving clinical benefit for calcific aortic stenosis. Pelacarsen, a hepatocyte-directed antisense oligonucleotide that suppresses apo(a) production, reduced Lp(a) by as much as 80% in phase 2 studies among participants with pre-existing cardiovascular disease. The small interfering RNA olpasiran exceeded 95% reduction at higher phase 2 doses; lepodisiran produced more than 90% reduction with prolonged effects, and zerlasiran lowered time-averaged concentrations by more than 80%. The oral assembly inhibitor muvalaplin produced dose-dependent reductions of up to roughly 86% over 12 weeks in phase 2 testing. These results demonstrate that Lp(a) can be suppressed, but no completed trial has shown that the biomarker change translates into slower valve calcification or better clinical outcomes. The double-blind, placebo-controlled Lp(a)FRONTIERS CAVS trial is recruiting an estimated 502 patients with calcific aortic stenosis to test monthly pelacarsen directly, with primary trial completion projected for March 2030. Whether treatment works may depend on disease stage, treatment duration, the magnitude of suppression and the biomarkers that best predict response; future trials will need to distinguish disease prevention from modification of established stenosis, recruit diverse populations, standardize assays and combine imaging measures with clinical outcomes.

Subject of Research: Lipoprotein(a) as a causal factor and therapeutic target in calcific aortic stenosis

Article Title: Lipoprotein(a) in calcific aortic stenosis: mechanistic insights, clinical evidence, and emerging therapies

Article References: Li, W., Shuang, S. Y., An, Y. B., Yao, X., Hao, W., Sheng, X. X., Lian, P. X., & Feng, M. Q. (2026). Lipoprotein(a) in calcific aortic stenosis: mechanistic insights, clinical evidence, and emerging therapies. Frontiers in Cardiovascular Medicine, 13, Article 1963618. https://doi.org/10.3389/fcvm.2026.1963618

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1963618

Keywords: lipoprotein(a), calcific aortic stenosis, aortic valve calcification, oxidized phospholipids, autotaxin, pelacarsen, Lp(a) lowering, LPA gene, valve inflammation, clinical trials, Lipoprotein, calcific

A team at the Medical University of Innsbruck, led by Magdalena Holzknecht and Martin Reindl, examined whether lipoprotein(a), a genetically determined particle increasingly flagged as an independent cardiovascular risk factor, influences the extent of myocardial and microvascular damage in patients suffering their first ST-elevation myocardial infarction, the most severe form of heart attack. The findings, published open access in Clinical Research in Cardiology, reveal a striking dissociation: while conventional LDL cholesterol was measurably linked to larger infarcts and more severe microvascular injury, lipoprotein(a) showed no meaningful association with any of these damage patterns, nor with medium-term clinical outcomes.

The study drew on the prospective MARINA-STEMI cohort, in which 518 patients with a median age of 59 years, 19 percent of them women, were treated with primary percutaneous coronary intervention between 2018 and 2024. All participants met strict criteria: a first STEMI confirmed by European and American cardiology committee standards, revascularization within twelve hours of symptom onset, and no prior myocardial infarction or coronary intervention. Blood drawn at coronary care unit admission allowed the researchers to quantify lipoprotein(a) using a particle-enhanced immunological turbidity test on a Roche cobas system, alongside total, LDL and HDL cholesterol. Median lipoprotein(a) at admission was 27 nmol/l, with an interquartile range of 20 to 90 nmol/l, while median LDL cholesterol stood at 141 mg/dl.

The real power of the investigation lay in its imaging. Every patient underwent multiparametric cardiovascular magnetic resonance on a 1.5-Tesla Siemens MAGNETOM Avanto fit scanner, first within the first week after PCI and again after four months. The standardized protocol combined high-resolution cine imaging with a voxel size of 1.5 by 1.5 by 6.0 millimeters to capture left ventricular volumes and ejection fraction, late gadolinium enhancement imaging roughly fifteen to twenty minutes after contrast administration to delineate infarct size, and T2* mapping performed before contrast to detect intramyocardial hemorrhage and persistent iron deposition in the infarct core. Infarct size, expressed as a percentage of total left ventricular myocardial mass, was quantified by identifying areas of hyperenhancement exceeding the signal intensity of remote myocardium by more than five standard deviations.

The baseline scan, performed at a median of four days after PCI, revealed a median infarct size of 14 percent of left ventricular myocardial mass. Intramyocardial hemorrhage, the hallmark of severe microvascular injury, was present in 33 percent of patients, and microvascular obstruction in 54 percent. By the four-month follow-up, infarct size had decreased to a median of 12 percent, hemorrhage persisted in 23 percent as iron deposition within the infarct core, and microvascular obstruction had largely resolved, affecting just 11 percent of patients. These tissue-level markers are considered the gold standard for gauging reperfusion injury and are strongly linked to both short- and long-term prognosis after STEMI.

Against this backdrop, the lipid comparisons produced a clear split. LDL cholesterol correlated significantly with infarct size both at baseline and at four months, with Spearman coefficients of 0.114 and 0.119 respectively, and patients with infarcts at or above the cohort median had higher LDL concentrations than those with smaller infarcts. LDL was also elevated in patients with intramyocardial hemorrhage, 145 versus 140 mg/dl, and in those with microvascular obstruction, 144 versus 138 mg/dl. Total cholesterol followed the same pattern. Lipoprotein(a), in contrast, showed no correlation with infarct size at either time point, no difference between patients with and without hemorrhage, 25 versus 28 nmol/l, and no association with microvascular obstruction or persistent iron deposition. Even when the researchers applied logistic regression and adjusted for ischemic time, an important determinant of large infarcts, the estimate for lipoprotein(a) remained essentially unchanged and statistically neutral.

The clinical endpoint reinforced the imaging story. Elevated lipoprotein(a), defined as 105 nmol/l or higher according to current guideline thresholds, was present in 22 percent of the cohort, 114 patients. Over a median follow-up of 21 months, 45 patients, roughly 9 percent, experienced a major adverse cardiovascular event, a composite of all-cause death, re-infarction, or new congestive heart failure, including 16 deaths, 16 re-infarctions and 13 heart failure events. The MACE rate was virtually identical in patients with and without elevated lipoprotein(a), 8.8 versus 8.7 percent, and Kaplan–Meier analysis of MACE-free survival showed no separation between the groups. Statin therapy, initiated in 99 percent of patients by discharge and maintained in 83 percent throughout follow-up, likewise showed no association with the exploratory clinical outcomes.

Why would a particle so firmly established as a lifetime risk factor for coronary artery disease fail to leave a fingerprint on the acute injury itself? The Innsbruck investigators point to a fundamental temporal distinction in how these lipids operate. LDL is a dynamic molecule directly embedded in the pathophysiology of the acute event: it drives lipid-rich plaque formation, raises thrombus burden with heightened risk of distal embolization, promotes endothelial oxidative stress, and contributes to the no-reflow phenomenon that starves the microcirculation after epicardial reperfusion. Lipoprotein(a), by contrast, may exert its pro-atherogenic and pro-inflammatory effects over decades, fueling chronic plaque development and instability through oxidized phospholipids that elicit arterial wall inflammation, rather than modulating the downstream myocardial damage once the artery has been reopened. In the context of timely reperfusion with primary PCI, the severity of tissue injury may be governed largely by total ischemic time, culprit vessel patency, reperfusion injury and individual microcirculatory susceptibility, factors that sit downstream of any individual’s lipoprotein(a) level.

The authors are careful to frame the conclusions within the study’s limits. The observational design precludes causal inference, the 9 percent event rate and limited follow-up may have reduced statistical power to detect subtle outcome differences, and the findings apply to stable STEMI patients suitable for CMR imaging rather than to delayed-reperfusion or non-STEMI populations. Women, at 19 percent of the cohort, remain underrepresented, a proportion consistent with previous CMR-based STEMI studies but still a caveat for generalizability. The clinical outcome analysis was explicitly exploratory and confined to the early post-infarction phase.

Nevertheless, the message for clinicians and researchers is consequential. Lipoprotein(a) should primarily be regarded as a risk-enhancing factor for the development of cardiovascular events, the authors conclude, rather than as a marker of infarct severity once STEMI has occurred. With potent lipoprotein(a)-lowering therapies, including antisense oligonucleotides and small interfering RNAs, now being tested in people with established cardiovascular disease, the study suggests these agents are unlikely to shrink infarcts or rescue the microcirculation in the acute setting, even as they may prove valuable for long-term prevention. For the 518 patients whose hearts were scanned in extraordinary detail, the fats that built their plaques over a lifetime told one story, while the damage inflicted in the hours around reperfusion told quite another.

Subject of Research: Cardiology

Article Title: Association of lipoprotein(a) with ischemia–reperfusion injury in patients with ST-elevation myocardial infarction

Article References: Holzknecht, M., Tiller, C., Lechner, I., Oberhollenzer, F., Kaser, A., Fischer, P., Sandor, A., Gollmann-Tepeköylü, C., Mayr, A., Bauer, A., Metzler, B., Reinstadler, S. J., & Reindl, M. (2026). Association of lipoprotein(a) with ischemia–reperfusion injury in patients with ST-elevation myocardial infarction. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03044-9

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03044-9

Keywords: lipoprotein(a), STEMI, ischemia-reperfusion injury, cardiovascular magnetic resonance, LDL cholesterol, microvascular injury, myocardial infarction, Association, lipoprotein, ischemia, reperfusion, injury

The research, published in the European Heart Journal, was led by Clemens Wittenbecher, Assistant Professor of Precision Medicine and Diagnostics at Chalmers, with postdoctoral fellow Jakub Morze as lead author. The team undertook an unusually ambitious measurement campaign: using blood samples from around 35,000 participants in the UK Biobank who had no previous history of heart disease, they measured nearly 3,000 different proteins circulating in the blood. They then combined this proteomic data with genetic information and long-term health records, allowing them to ask a deceptively simple question: what is happening in the bodies of people who remain at risk even after their cholesterol numbers look healthy?

To understand why the question matters, it helps to look at the scale of the problem. According to the World Health Organization, nearly 17.9 million people die from cardiovascular diseases worldwide every year, and heart attacks and strokes account for more than four out of five of those deaths. Coronary heart disease develops when fatty material accumulates in the blood vessels that supply the heart, a process known as atherosclerosis. If a plaque formed from this fatty material ruptures, a clot can rapidly form and block the vessel entirely, cutting off blood flow to the heart muscle. High blood cholesterol remains one of the most important modifiable risk factors for this process, which is why statins and other lipid-lowering therapies dominate modern prevention.

Cholesterol itself is not a villain. It is a fat-like substance that is essential for building cells and producing certain vitamins and hormones. The trouble arises when it is transported in excess. Cholesterol and other fats cannot travel freely through the watery bloodstream, so they are packaged into specialised particles called lipoproteins. Three classes of these particles share a structural surface protein called apolipoprotein B, or apoB, and when present in excess, all three can deposit cholesterol into the walls of blood vessels. Because of this shared capacity for harm, the cholesterol they carry is collectively labelled bad cholesterol, even though the particles themselves behave in distinctly different ways.

Low-density lipoprotein, or LDL, is the most abundant of these apoB-containing particles and carries the majority of cholesterol in the blood. Standard clinical tests measure the cholesterol inside these particles, but the Chalmers group’s previous work had already suggested that counting the particles themselves is a more effective way of predicting future heart disease. Beyond LDL, two other particles attracted the researchers’ attention. Triglyceride-rich lipoproteins, known as TRL, carry triglycerides, a major source of energy for the body, along with cholesterol; as triglycerides are removed from these particles, they leave behind remnants that can deposit cholesterol in artery walls. Lipoprotein(a), or Lp(a), is an LDL-like particle with an additional protein called apolipoprotein(a), and elevated levels of it are an established risk factor for coronary heart disease.

Crucially, the earlier work by the same research group had shown that TRL and Lp(a) appear to be more harmful per particle than LDL, and the two are believed to represent the main remaining risk particles for heart disease once LDL cholesterol has been brought down to a healthy level. What remained unclear was why. For this study, the team wanted to understand what happens beyond the simple accumulation of cholesterol in artery walls, whether different fat-carrying particles can damage blood vessels differently, and why the remaining risk persists in some people. Proteomics, the large-scale and systematic study of all the proteins present in a body fluid at a given moment, offered a way in.

Unlike genomics, which examines fixed DNA, proteomics captures the dynamic, working machinery of biology. Proteins build tissues, digest food, send hormonal signals and fight infections, and their composition shifts in response to diet, stress, aging and disease. Measuring them therefore provides something close to a real-time snapshot of how the body is actually functioning. By combining measurements of almost 3,000 blood proteins with genetic data and long-term health records, the researchers identified protein patterns that offer new clues about how lipid particles may damage arteries, and about which biological pathways are activated in the people who go on to develop disease.

The most striking discovery was an overlap. The protein patterns associated with the risk particles beyond LDL, namely TRL and Lp(a), pointed toward the future onset of heart disease, and the two particle types shared many of the same protein signatures and harmful biological effects despite being chemically distinct. These particles were shown to contain proteins that attract immune cells, a process that could contribute to inflammation and structural changes in the walls of blood vessels. In other words, TRL and Lp(a) may not merely deliver cholesterol to artery walls; they may actively recruit the immune machinery that drives atherosclerosis forward. The protein pattern for LDL, by contrast, was mainly associated with the build-up of cholesterol in artery walls, a more classical mechanism.

For Morze, the convergence between TRL and Lp(a) is one of the most interesting findings of the study. It suggests that these two particle types may affect some of the same inflammatory and vascular processes, which could help identify targets for more precisely directed prevention in the future. If TRL remnants and Lp(a) are indeed harming vessels through shared inflammatory pathways, then therapies aimed at those pathways, rather than at cholesterol alone, might address the risk that today’s treatments leave behind. The authors are careful to note the boundaries of the work: the study did not test a new treatment, and it did not establish a protein-based test ready for clinical use. Its contribution is mechanistic, mapping the biological processes that connect specific lipoproteins to arterial damage in a very large human cohort.

Wittenbecher emphasises that the established pillar of prevention stands firm. Lowering LDL cholesterol remains a cornerstone of cardiovascular protection, and nothing in the new findings changes that. What the study adds is a plausible explanation for the risk that remains beyond LDL, along with a research agenda for testing whether measuring or targeting the newly identified processes can improve prevention alongside existing treatments. The research was a genuinely international collaboration, with authors active at Chalmers and the University of Gothenburg in Sweden, Harvard Medical School and the Harvard T.H. Chan School of Public Health in the United States, AstraZeneca, the University of Copenhagen, the University of Minnesota, the Lundquist Institute at Harbor-UCLA, the University of Glasgow and a municipal hospital in Olsztyn, Poland. As proteomic profiling becomes faster and cheaper, studies of this kind may move from explaining residual risk to predicting it in individual patients, opening the door to a future in which heart disease prevention is tailored not just to a cholesterol number, but to the full molecular story unfolding in a person’s blood.

Subject of Research: Proteomic profiling of apolipoprotein B-containing lipoproteins to explain residual coronary heart disease risk beyond LDL cholesterol

Article Title: Beyond ‘bad’ cholesterol: new clues to the risk of heart disease

Article References: Beyond ‘bad’ cholesterol: new clues to the risk of heart disease. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cardiovascular disease, LDL cholesterol, lipoprotein(a), triglyceride-rich lipoproteins, proteomics, atherosclerosis, UK Biobank, apolipoprotein B, inflammation, precision medicine, European Heart Journal, residual risk

Enlicitide, known during development as MK-0616, is an orally bioavailable macrocyclic peptide that binds circulating PCSK9, the protein that normally marks liver LDL receptors for destruction. By blocking the interaction between PCSK9 and the hepatic LDL receptor, enlicitide prevents receptor degradation and increases receptor recycling to the hepatocyte surface, thereby accelerating clearance of LDL particles from the bloodstream. This mechanism mirrors that of injectable monoclonal antibody PCSK9 inhibitors such as evolocumab and alirocumab, which have already demonstrated major cardiovascular benefit in landmark outcomes trials like FOURIER and ODYSSEY OUTCOMES. The difference is delivery: enlicitide is taken by mouth, potentially sidestepping the cost, access barriers, and needle aversion that have limited broader uptake of injectable agents.

The research team, registered with PROSPERO and conducted according to PRISMA 2020 guidelines, searched PubMed, Embase, Scopus, and ClinicalTrials.gov from inception through March 2026. From 458 initial records, only three trials met the strict eligibility criteria: adults with primary or heterozygous familial hypercholesterolemia and elevated LDL cholesterol despite standard therapy, randomized to enlicitide or placebo. The evidence base comprised the multinational Phase 3 trial by Navar and colleagues enrolling 2909 participants across 14 countries and testing 20 mg once daily for 52 weeks; the Phase 2b dose-ranging trial by Ballantyne and colleagues with 381 participants testing 6, 12, 18, and 30 mg doses over 8 weeks; and a second Phase 3 trial of 303 participants taking 20 mg or placebo for 52 weeks.

The headline result was unambiguous. Across six comparisons from the three trials, enlicitide reduced LDL cholesterol from baseline by a mean difference of 56.19 percent relative to placebo, with a 95 percent confidence interval of 64.14 to 48.25 percent reduction and a p-value below 0.0001. The 95 percent prediction interval, which projects the range of true effects expected in future similar trials, spanned 72.18 to 40.21 percent reduction, meaning a clinically meaningful benefit would be anticipated in essentially any comparable setting. Heterogeneity was moderate at 56.9 percent, and a leave-one-out sensitivity analysis confirmed that no single trial arm drove the overall conclusion.

Dose-response patterns added pharmacological texture to the findings. In the Phase 2b dose-ranging trial, LDL cholesterol reduction was numerically greatest at the 30 mg dose, reaching a mean difference of 60.90 percent, though formal subgroup testing across doses did not reach statistical significance. Importantly, a homogeneity-restricted sensitivity analysis limited to the optimized 20 mg dose at the common 24-week primary endpoint of the two Phase 3 trials, covering 3049 participants, produced an even tighter estimate: a 60.39 percent reduction with a confidence interval of 64.76 to 56.01 percent and zero heterogeneity. Treatment duration also mattered little for the core lipid markers, with no significant difference between 8-week and 52-week comparisons.

The benefits extended well beyond LDL cholesterol alone. Non-HDL cholesterol fell by 51.36 percent, apolipoprotein B by 47.09 percent, and lipoprotein(a) by 20.10 percent, all statistically significant with prediction intervals excluding the null. Triglycerides declined by 13.12 percent, though the prediction interval for that outcome crossed the null, suggesting less consistency. The apolipoprotein B and non-HDL cholesterol reductions are particularly noteworthy because emerging evidence positions these markers as complementary targets that may capture residual atherogenic risk not fully reflected by LDL cholesterol. The lipoprotein(a) finding carries its own intrigue: it was the only outcome showing a duration-related difference, with larger reductions at 52 weeks than at 8 weeks, raising the possibility that this effect deepens with longer exposure, although the authors caution this remains exploratory.

Safety results were broadly reassuring but nuanced. Any adverse event showed a statistically significant but clinically marginal increase with enlicitide, a risk ratio of 1.03 driven overwhelmingly by the largest trial, which contributed 80.4 percent of the pooled weight. More strikingly, serious adverse events were significantly reduced with enlicitide, a risk ratio of 0.84, though the authors urge caution because the prediction interval crossed 1.0 and a single trial supplied 95.7 percent of the weight. Moderate-to-severe adverse events showed no significant difference, and there was a non-significant trend toward fewer treatment discontinuations due to adverse events in the enlicitide group. All-cause mortality was essentially identical between groups. Notably, new-onset or worsening diabetes occurred at comparable rates, and no cases of drug-induced liver injury were reported, consistent with the established safety record of the injectable PCSK9 inhibitor class.

The methodological rigor of the analysis lends weight to its conclusions. The investigators used a random-effects model with restricted maximum-likelihood estimation, applied the conservative Hartung-Knapp adjustment to confidence intervals, and calculated prediction intervals based on the t-distribution. Risk of bias assessment using the Cochrane RoB 2.0 tool rated two trials at low risk overall and one with some concerns, with no trial judged high risk. Certainty of evidence, graded with the GRADE framework, reached moderate for all five lipid outcomes but dropped to low or very low for the safety endpoints, reflecting imprecision and indirectness. The authors also handled a subtle statistical pitfall: because the dose-ranging trial shared a single placebo group across four dose arms, they apportioned the placebo sample size across pairwise comparisons to avoid double-counting, in line with Cochrane Handbook guidance.

Important caveats temper the enthusiasm. All included trials were industry-sponsored, follow-up did not extend beyond 52 weeks, and the entire evidence base rests on surrogate lipid endpoints rather than hard cardiovascular outcomes. The dedicated cardiovascular outcomes trial for enlicitide is still ongoing, and until it reports, the drug’s ability to prevent heart attacks and strokes remains inferred rather than proven. The Phase 3 regimen also required fasting conditions, with participants instructed to take the pill on an empty stomach and avoid food and beverages other than water for 30 minutes afterward. Adherence to both the drug and fasting instructions exceeded 97 percent under controlled trial conditions, but whether such discipline translates to routine clinical practice remains an open question.

Still, the trajectory is familiar and encouraging. Injectable PCSK9 inhibitors followed the same path: robust LDL lowering in surrogate-endpoint trials first, then definitive cardiovascular benefit in large outcomes studies. In the CORALreef Lipids trial, more than 70 percent of participants achieved LDL cholesterol below 70 mg/dL with at least a 50 percent reduction from baseline, and roughly two-thirds reached the more stringent target of below 55 mg/dL. If enlicitide clears its outcomes trial and real-world adherence hurdles, it could reshape the treatment landscape for the substantial proportion of high-risk patients who remain above guideline-recommended LDL targets, offering potent lipid lowering in a form many more patients would actually take.

Subject of Research: Efficacy and safety of the oral PCSK9 inhibitor enlicitide in hypercholesterolemia

Article Title: Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Article References: Farhan, M., Murtaza, M., Rasool, M. M., Khan, F., Amjad, H., Rai, K. D., Ali, S. M. E., Raza, A. A., Sohail, M. A., Samadi, A., & Hassan, F. (2026). Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism, 9(6), Article e70358. https://doi.org/10.1002/edm2.70358

Image Credits: AI Generated

DOI: 10.1002/edm2.70358

Keywords: enlicitide, PCSK9 inhibitor, LDL cholesterol, hypercholesterolemia, meta-analysis, cardiovascular disease, apolipoprotein B, lipoprotein(a), statins, oral peptide drug, lipid-lowering therapy, randomized controlled trials

Lipoprotein(a), abbreviated Lp(a), is structurally an LDL particle with a twist. It contains apolipoprotein B100 covalently linked, in a one-to-one molar ratio, to apolipoprotein(a), a glycoprotein whose gene sits on chromosome 6 and shares more than 80 percent structural homology with plasminogen, the key enzyme precursor of blood clot dissolution. Apolipoprotein(a) is built from repeated kringle domains, and one of them, kringle 4 type 2, is present in a variable number of copies, usually between 3 and more than 40. This copy number varies enormously between individuals and ancestry groups and is the major determinant of both the size of the particle and the concentration of Lp(a) in plasma: smaller isoforms are secreted more efficiently by hepatocytes, so people carrying fewer repeats tend to have higher circulating levels. The entire production process occurs in the liver, where apo(a) and apoB are secreted separately and assembled into mature Lp(a) particles outside the cell.

The scientific history of Lp(a) is a story of enthusiasm, disappointment, and redemption. After observational studies in the late 1980s linked plasma levels to coronary heart disease, early prospective trials produced discordant results, and because no diet or drug could reliably lower the particle, interest waned for roughly two decades. That picture changed dramatically with population-based studies, meta-analyses, genome-wide association studies, and Mendelian randomization analyses, which together established Lp(a) as a strong, independent, and genetically determined causal risk factor for atherosclerotic cardiovascular disease. Plasma Lp(a) measurement now reclassifies the risk category of approximately 40 percent of primary prevention patients who sit in the intermediate band of the Framingham risk score, and recent guidelines recommend widespread testing. Values above 50 mg/dL, or 125 nmol/L, are conventionally considered elevated; roughly 15 to 20 percent of people worldwide exceed this threshold, and the population distribution is strongly skewed, ranging from less than 0.2 to more than 200 mg/dL.

The concept of residual cardiovascular risk is central to the review’s argument. Even when blood pressure, LDL cholesterol, blood glucose, obesity, and smoking are treated to the best standards of care, a substantial probability of major adverse cardiovascular events remains. The evidence is striking. In the PRIME study, which followed 9,649 men aged 50 to 59 for ten years, treated hypertensive patients had a 50 percent higher relative risk of major cardiovascular events after adjustment for concurrent risk factors. In the Framingham Offspring Cohort, treated hypertensive patients whose blood pressure was below 140/90 mm Hg still carried a 50 percent higher risk of cardiovascular events than untreated subjects with comparable readings. On the lipid side, long-term reassessments of early statin trials show a residual risk of approximately 30 percent, and even trials of the most potent PCSK9 inhibitors, which drove LDL cholesterol to a median below 30 mg/dL, could not normalize cardiovascular risk. A recent participant-level meta-analysis demonstrated that effective LDL reduction does not offset Lp(a)-related risk: participants with Lp(a) above 50 mg/dL and LDL below 77 mg/dL still had a 38 percent greater risk than patients with lower Lp(a) levels.

What makes Lp(a) especially relevant to kidney disease is that the kidney itself appears to be a major site of Lp(a) clearance. Clinical studies consistently show that plasma Lp(a) rises progressively as glomerular filtration rate falls, and the review’s authors contributed their own evidence: in 417 patients with arterial hypertension, 160 of whom had hypertensive nephroangiosclerosis with creatinine clearance between 30 and 89 mL/min/1.73 m², Lp(a) levels were significantly higher in those with renal involvement, correlated inversely with creatinine clearance, and were associated with more prevalent coronary, cerebrovascular, and peripheral artery disease. Notably, urinary albumin losses did not correlate with Lp(a) levels and apo(a) phenotype distribution was comparable across levels of kidney function, suggesting that kidney damage itself, rather than altered isoform expression, drives the increase. Stable isotope turnover studies and urinary apo(a) clearance studies support the conclusion that elevated Lp(a) in chronic kidney disease reflects reduced renal clearance rather than increased hepatic production.

Prospective cohort data now confirm that this biochemical elevation translates into clinical harm. In the Chronic Renal Insufficiency Cohort study, 3,744 participants followed for 7.5 years showed that those in the highest quartile of Lp(a), above 61.3 mg/dL, had a 49 percent higher risk of myocardial infarction and a 28 percent higher risk of death. The German Chronic Kidney Disease study, which followed 5,043 subjects for 6.5 years, found that each 10 mg/dL increase in Lp(a) raised cardiovascular disease risk by 6.5 percent, with risk climbing more than 30 percent in subjects above 70 mg/dL regardless of traditional risk factors. A systematic review of 15 studies encompassing 12,260 participants with kidney disease confirmed that high Lp(a) independently predicts cardiovascular events and death, and data from the China Renal Data System, covering more than 50,000 participants, linked rising Lp(a) to both progression of renal failure and cardiovascular mortality. The particle is also entwined with calcific aortic valve disease, which frequently accompanies advanced kidney disease, although MESA study data on 6,346 subjects found the association between valve calcification and kidney dysfunction occurred independently of Lp(a) levels.

The dialysis and transplantation literature provides a natural experiment that strengthens the causal interpretation. Patients on hemodialysis have higher Lp(a) than healthy subjects and patients with early kidney disease, and peritoneal dialysis patients show elevations independent of apo(a) isoform size. Crucially, neither hemodialysis nor peritoneal dialysis lowers Lp(a), whereas renal transplantation significantly reduces it, a rapid change consistent with the restoration of renal clearance. In nephrotic syndrome, where heavy urinary protein wasting raises Lp(a) independently of filtration rate, levels normalize after remission of the causative condition, likely reflecting increased hepatic synthesis rather than impaired catabolism. Together these observations justify repeated Lp(a) measurements during the course of progressive kidney disease, since levels fluctuate with inflammatory states and changes in treatment even though they are largely stable over time in the general population.

The therapeutic landscape is changing rapidly. Traditional lipid-lowering drugs have negligible effects on Lp(a), and dietary interventions are unpredictable at best, although replacing saturated fatty acids with unsaturated fats and long-chain carbohydrates produces small reductions. The PCSK9 inhibitors evolocumab and alirocumab lower Lp(a) by only about 27 and 23 percent respectively, from baseline levels that were mostly well below risk thresholds. The new generation of agents is different. Pelacarsen, an antisense oligonucleotide delivered to hepatocytes via the asialoglycoprotein receptor, degrades LPA mRNA and reduced Lp(a) by 80 percent at a dose of 20 mg weekly over six months. Small interfering RNAs conjugated with N-acetyl-galactosamine, including olpasiran, zerlasiran, and lepodisiran, harness the RNA-induced silencing complex to the same end: olpasiran achieved placebo-adjusted reductions of 97 percent, zerlasiran 95 percent with a single 450 mg dose, and lepodisiran 94 percent with 400 mg. Muvalaplin, an oral small molecule that blocks the kringle 4-mediated interaction between apo(a) and apoB, reduced Lp(a) by 86 percent at 240 mg per day over three months. Phase 3 outcome trials such as Lp(a)HORIZON, OCEAN(a), and ACCLAIM-Lp(a) are now testing whether these dramatic biochemical reductions translate into fewer cardiovascular events.

There is, however, a critical caveat for the kidney community: every trial of these investigational drugs excluded patients with advanced chronic kidney disease or on dialysis, so efficacy, dosing, and long-term safety in renal patients remain unknown and cannot be extrapolated. In the meantime, the review’s authors emphasize that rigorous application of proven preventive measures remains essential, including smoking cessation, salt restriction, exercise, blood pressure targets below 130/80 mm Hg with renin-angiotensin system inhibitors, glycated hemoglobin below 7.0 percent, SGLT2 inhibitors, GLP-1 receptor agonists, finerenone, and intensive lipid lowering to LDL below 55 mg/dL using statins, ezetimibe, and PCSK9 inhibitors as needed. For selected high-risk patients with elevated Lp(a), lipoprotein apheresis offers an existing, if cumbersome, option: retrospective series report reductions from a mean of 138 mg/dL to 51 mg/dL with a 94 percent reduction in major cardiovascular events over four years, and in nine hemodialysis patients undergoing combined apheresis, median Lp(a) fell from 242.7 to 64.2 nmol/L with a 57 percent reduction in adverse cardiac and vascular events over four years.

A landmark Mendelian randomization analysis adds a note of scientific caution: genetically predicted lifelong differences in Lp(a) correspond to an estimated 6 percent decrease in atherosclerotic cardiovascular disease odds for every 10 mg/dL reduction, but such estimates cannot be directly translated into the expected effect of short-term pharmacological lowering, and meaningful clinical benefit would likely require reductions greater than 50 mg/dL. Still, with new therapies capable of cutting Lp(a) by up to 90 percent from baseline, the potential is enormous. If ongoing trials demonstrate that profound Lp(a) reduction lowers residual cardiovascular risk, and if dedicated studies in patients with kidney disease follow, Lp(a) could be transformed from a passive risk marker into a primary therapeutic target for one of the most vulnerable populations in cardiovascular medicine.

Subject of Research: The role of lipoprotein(a) in residual cardiovascular risk among patients with chronic kidney disease and emerging Lp(a)-lowering therapies

Article Title: Lipoprotein(a): a potential target for the reduction of residual cardiovascular risk in patients with chronic kidney disease

Article References: Sechi, L. A., Bulfone, L., Vacca, A., Comand, J., Marcante, S., Brosolo, G., Pagano, C., & Catena, C. (2026). Lipoprotein(a): a potential target for the reduction of residual cardiovascular risk in patients with chronic kidney disease. Frontiers in Nephrology, 6, Article 1950030. https://doi.org/10.3389/fneph.2026.1950030

Image Credits: AI Generated

DOI: 10.3389/fneph.2026.1950030

Keywords: lipoprotein(a), chronic kidney disease, residual cardiovascular risk, atherosclerotic cardiovascular disease, antisense oligonucleotides, small interfering RNA, pelacarsen, olpasiran, muvalaplin, lipoprotein apheresis, renal clearance, cardiovascular prevention

Evolocumab belongs to a class of drugs known as PCSK9 inhibitors, and its mechanism is elegantly simple at the molecular level. PCSK9 is a protein produced by the liver that binds to LDL receptors on hepatocytes and tags them for destruction. Because these receptors are the primary route by which the liver clears LDL particles from the bloodstream, destroying them means cholesterol lingers in circulation, embedding itself in arterial walls. Evolocumab is a fully human monoclonal antibody that neutralises PCSK9, preventing this degradation. The result is a dramatic increase in the recycling and surface density of LDL receptors, which accelerates the clearance of LDL particles and can lower LDL cholesterol by up to 60 percent, far beyond what statins alone typically achieve.

The new analysis was conducted under PRISMA guidelines and prospectively registered, with researchers searching five major databases through April 2025. They included only randomised controlled trials of evolocumab in adults with established cardiovascular disease, defined as prior myocardial infarction, stroke, symptomatic peripheral artery disease, or coronary revascularisation. By focusing exclusively on a single PCSK9 inhibitor rather than pooling multiple agents, the investigators aimed to produce drug-specific estimates while minimising the heterogeneity that plagues broader class-level reviews. The final dataset encompassed 67,662 patients, with 34,618 receiving evolocumab and 33,044 receiving placebo or standard therapy, spanning landmark trials such as FOURIER, its open-label extension, and EVOPACS, which enrolled patients in the immediate aftermath of acute coronary syndromes.

The lipid results were striking across the board. Beyond the headline LDL reduction of 57.73 milligrams per decilitre, evolocumab lowered total cholesterol by about 52 milligrams per decilitre and triglycerides by roughly 21 milligrams per decilitre, while modestly raising HDL cholesterol by about 3.7 milligrams per decilitre. The drug also reduced lipoprotein(a), a genetically determined, pro-atherogenic particle that statins barely touch, though the pooled reduction of about 11 milligrams per decilitre narrowly missed conventional statistical significance. The authors caution that the clinical benefit should be attributed primarily to LDL lowering, which has a firmly established causal relationship with atherosclerotic risk, while the changes in HDL and triglycerides are best viewed as accompanying metabolic effects rather than independent drivers of outcome improvement.

On the clinical side, the pooled analysis found a significant reduction in major adverse cardiovascular events, with a risk ratio of 0.53. That figure, however, demands careful interpretation. The pooled estimate is considerably larger than the roughly 15 percent relative risk reduction reported in the FOURIER trial, and the researchers attribute this discrepancy to methodological differences, including the pooling of risk ratios from aggregated event counts rather than hazard ratios from time-to-event analyses, the inclusion of smaller trials with fewer events, and variation in how composite endpoints were defined across studies. When the most influential smaller trials were excluded in sensitivity analyses, heterogeneity vanished and the effect settled at a more conservative risk ratio of 0.84, which aligns closely with the landmark trial evidence.

Individual endpoints told a consistent story. Myocardial infarction risk fell by 26 percent and coronary revascularisation by 20 percent, both with high-certainty evidence and minimal heterogeneity. Stroke showed a smaller, borderline significant reduction of 14 percent. Cardiovascular mortality and hospitalisation for unstable angina did not decline significantly, which the authors attribute to the relative rarity of these individual endpoints, the limited follow-up duration of most trials, and the fact that cardiovascular death reflects many competing mechanisms beyond LDL exposure alone. Importantly, the absence of significance for these endpoints does not negate biological benefit, given the robust reductions observed in the events that most directly reflect plaque rupture and arterial obstruction.

Safety findings were equally reassuring. Across more than 56,000 patients analysed for serious adverse events, there was no difference between evolocumab and control groups, with zero heterogeneity indicating remarkably consistent results. Rates of drug discontinuation, neurocognitive complaints, muscle-related symptoms, and new-onset diabetes were all statistically indistinguishable from placebo. The only signal was a modest, non-significant increase in mild injection-site reactions. This profile contrasts favourably with statins, which do not inhibit intracellular cholesterol synthesis and therefore avoid the muscle toxicity pathway that troubles some patients. Long-term extension data from FOURIER-OLE, following patients for nearly eight years, have similarly found no accumulation of neurological, metabolic, or hemorrhagic harms.

The authors also explored how treatment effects varied across clinical contexts. LDL reductions remained significant in every subgroup examined, ranging from about 55 to 60 milligrams per decilitre whether patients had recent acute coronary syndromes or stable disease. Lipoprotein(a) reductions were significant in acute coronary syndrome populations and in event-driven trials, while the MACE benefit was concentrated in stable atherosclerotic disease populations, imaging trials, and studies with at least one year of follow-up. These patterns reinforce the idea that the magnitude of absolute benefit scales with baseline cardiovascular risk, meaning patients with recent events, polyvascular disease, diabetes, or persistently elevated cholesterol stand to gain the most from adding evolocumab to their regimen.

The clinical implications extend to health economics as well. Current guidelines from the American College of Cardiology, the American Heart Association, and the European Society of Cardiology already recommend PCSK9 inhibitors for patients whose LDL remains at or above 70 milligrams per decilitre despite maximally tolerated statin therapy. This analysis supports that guidance, but the authors note that cost remains a barrier, with earlier cost-effectiveness analyses favourable only for the highest-risk subgroups. Insurers frequently require documented very high LDL or multiple cardiovascular events before approving coverage, a practice that effectively targets the patients most likely to benefit. As prices fall and value-based pricing models mature, access is expected to broaden.

Looking forward, the researchers call for individual participant data meta-analyses to identify which patient characteristics predict the greatest benefit, dedicated trials in patients with elevated lipoprotein(a), head-to-head comparisons with alirocumab and newer agents such as inclisiran, and real-world registries to confirm the durability of benefit beyond the trial setting. For now, the evidence solidifies a central principle of modern cardiology: when it comes to LDL cholesterol, lower is better, and evolocumab offers a powerful, safe tool for pushing levels far below what statins alone can achieve in the patients who need it most.

Subject of Research: Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with established atherosclerotic cardiovascular disease

Article Title: Impact of Evolocumab on LDL‐Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta‐Analysis

Article References: Goel, A., Naveed, M. A., Tandel, H., Mahmood, A., Mukhlis, M., Reddy, K. S. V., Maloth, A. K., Chauhan, A., Ashwara, A., Verma, A., & Tahir, H. B. (2026). Impact of Evolocumab on LDL‐Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 9(6), Article e70355. https://doi.org/10.1002/edm2.70355

Image Credits: AI Generated

DOI: 10.1002/edm2.70355

Keywords: evolocumab, PCSK9 inhibitor, LDL cholesterol, cardiovascular disease, meta-analysis, FOURIER trial, myocardial infarction, coronary revascularisation, lipoprotein(a), statins, secondary prevention, monoclonal antibody

Lipoprotein(a) is a particle similar in structure to low-density lipoprotein cholesterol but carrying an additional protein called apolipoprotein(a), whose size varies from person to person because of genetic variation. Unlike most cardiovascular risk markers, Lp(a) levels are largely locked in at birth by genetics and remain relatively stable throughout life, which means a single measurement in adulthood can, in principle, characterize an individual’s lifelong exposure. High Lp(a) is recognized as an independent risk factor for atherosclerotic cardiovascular disease, and recent estimates cited by the Family Heart Foundation suggest that roughly one in five people carry levels high enough to matter for their long-term cardiovascular risk. Despite that prevalence, awareness of the biomarker remains strikingly low among clinicians, health system administrators, payors, and the general public, and the Foundation reports that about 99 percent of people in the United States have never had their Lp(a) measured at all.

The gap between guideline recommendations and everyday clinical practice is central to why the Foundation pursued a machine learning approach. Recently released United States dyslipidemia guidelines now recommend Lp(a) screening for all adults, a position known as universal screening. Yet translating that recommendation into routine care requires changes to electronic health record workflows, laboratory ordering practices, reimbursement structures, and clinician education, and the Foundation’s researchers argue that this integration will take many years, if not decades, to accomplish. In the interim, a targeted strategy offers a pragmatic bridge: rather than screening everyone at once, health systems can use predictive analytics to identify the patients within their existing records who are statistically most likely to have elevated Lp(a) and offer testing to them first. The new study provides evidence that this enrichment strategy can work at meaningful scale.

“Although, recently released U.S. dyslipidemia guidelines recommend Lp(a) screening for all adults, integrating this into routine clinical practice will take many years, if not decades,” said Diane MacDougall, vice president of Research at the Family Heart Foundation and principal author of the study. “The FIND Lp(a) model supports targeted screening by helping identify people most likely to have high Lp(a), accelerating the adoption of universal screening and creating more opportunities for individuals living with high Lp(a) and their healthcare teams to manage cardiovascular risk.” Her framing captures the dual purpose of the project: the model is presented not as a replacement for universal screening but as a way to accelerate progress toward it by demonstrating value, building institutional experience, and reaching high-risk patients sooner than a purely sequential rollout would allow.

Technically, the FIND Lp(a) Machine Learning Model is a central component of the Foundation’s Flag, Identify, Network, and Deliver quality improvement program, a framework that applies predictive analytics to data already stored in electronic medical records. The model examines patterns in routinely collected clinical information to estimate which adults are most likely to have high Lp(a), and health systems that implement the program then offer Lp(a) screening to the individuals the algorithm flags. Patients confirmed to have elevated levels receive appropriate clinical care and are invited to engage with the Family Heart Foundation for additional education and support, an arrangement designed to close the loop from prediction to diagnosis to management. Because the approach relies on data that health systems already collect, it avoids the need for new data capture infrastructure, which the Foundation identifies as one reason the model could be deployed in real clinical environments rather than remaining a research prototype.

The deployment record distinguishes the project from many machine learning initiatives in medicine, which frequently stall after publication without ever reaching operational use. The FIND Lp(a) model has already been successfully deployed at five large United States healthcare systems participating in the FIND Lp(a) Program, an initiative the Foundation created to catalyze Lp(a) screening nationwide. Through a Collaborative Learning Network, the Foundation and its five health system partners are prospectively validating the model’s real-world performance while sharing implementation best practices and developing sustainable approaches to screening and follow-up care. In addition to this prospective validation, the study team reports that further validation using both retrospective and prospective healthcare system data is currently ongoing, an effort intended to confirm that the enrichment observed in the Family Heart Database holds up across heterogeneous patient populations, record systems, and care settings.

The study’s methodology was classified as a data and statistical analysis investigation, and the research subject was people, reflecting the use of de-identified patient records rather than laboratory or animal models. The initial validation result, a greater than 2.2-fold enrichment of elevated Lp(a) among model-flagged patients, functions as a measure of precision: of the patients the model prioritizes, a substantially higher proportion turn out to have genuinely high Lp(a) than would be found by screening the cardiovascular disease population at random. For health system planners, that precision translates directly into efficiency. Every screening order directed at a model-flagged patient is more likely to return a clinically actionable result, reducing wasted testing, laboratory costs, and clinician time while still moving the institution toward the guideline-recommended goal of universal measurement.

The clinical rationale for finding these patients is grounded in the biology of the lipoprotein itself. Because Lp(a) is genetically determined, individuals with elevated levels cannot lower them substantially through diet or exercise in the way that other lipid measures can sometimes be modified, which makes awareness and risk management through other means especially important. Knowing one’s Lp(a) status can prompt more aggressive control of modifiable risk factors, earlier and more intensive monitoring, and appropriate family counseling, since the trait can be passed across generations. The Family Heart Foundation, founded in 2011 as the FH Foundation, has built its mission around exactly this problem, working to prevent heart attacks and strokes caused by familial hypercholesterolemia and elevated Lp(a), two common genetic disorders whose effects ripple through families and that frequently go undiagnosed until a cardiovascular event occurs.

The Foundation describes itself as a pioneer in applying real-world evidence, patient-driven advocacy, and multi-stakeholder education to inherited lipid disorders, and the FIND Lp(a) study fits that pattern by turning a large clinical database into a practical screening tool. The organization notes that it receives contributions and sponsorships from individuals, foundations, and pharmaceutical companies, and that this phase of the FIND Lp(a) initiative was funded by Novartis, although the company played no role in the study design, conduct, interpretation, or publication plans. For the broader field of cardiovascular prevention, the study offers a concrete demonstration that predictive analytics can be moved from theory into deployed clinical workflow, and that machine learning can serve as a bridge between what guidelines recommend and what health systems can realistically deliver. If ongoing validation confirms the initial results, targeted screening programs built on models like FIND Lp(a) could shorten the long road between a guideline recommendation and the day when the vast majority of Americans finally know their Lp(a) number.

Subject of Research: Machine learning-based targeted screening for elevated lipoprotein(a) in atherosclerotic cardiovascular disease

Article Title: Family Heart Foundation study demonstrates how the FIND Lp(a) machine learning model enables targeted Lp(a) screening

Article References: Family Heart Foundation study demonstrates how the FIND Lp(a) machine learning model enables targeted Lp(a) screening. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: lipoprotein(a), machine learning, cardiovascular disease, screening, Family Heart Foundation, predictive analytics, electronic health records, JACC: Advances, risk factors, guidelines, targeted screening, genetic risk

Lipoprotein(a), abbreviated Lp(a) and often pronounced simply as L-P-little-a, is a low-density lipoprotein particle to which an unusual protein called apolipoprotein(a) is covalently attached. Its concentration in blood is overwhelmingly dictated by the LPA gene, whose size polymorphisms vary dramatically across ethnic groups, and it has emerged over the past decade as one of the most powerful independent genetic risk factors for atherosclerotic cardiovascular disease, aortic valve stenosis and, in some studies, heart failure. Unlike LDL cholesterol, which responds robustly to diet, exercise and most lipid-lowering drugs, Lp(a) has historically resisted every lifestyle intervention thrown at it, fuelling the long-standing assumption that a single lifetime measurement is sufficient for risk stratification.

That assumption is precisely what the new study set out to test. A team of cardiologists and data scientists led by Ming-Lung Tsai of New Taipei Municipal TuCheng Hospital and Dong-Yi Chen of Linkou Chang Gung Memorial Hospital mined the Chang Gung Research Database, one of Taiwan’s largest multi-hospital electronic health record systems, for adults who had at least two Lp(a) measurements taken at least one year apart between January 2004 and December 2019. The retrospective cohort design allowed the researchers to observe how the biomarker drifted, or failed to drift, across a mean follow-up of 5.2 years, with some individuals contributing data across nearly the entire fifteen-year window.

The headline result is one of striking stability. Among the 17,363 participants, who had a mean age of 42.1 years and were 73.3 percent male, the median Lp(a) concentration actually declined slightly over follow-up, falling from 9.3 milligrams per deciliter at baseline to 7.4 milligrams per deciliter at the final measurement. Only 479 participants, a mere 2.8 percent of the cohort, showed an increase of 10 milligrams per deciliter or more, the threshold the investigators pre-specified as a clinically meaningful elevation. For the overwhelming majority, the genetic determinism model of Lp(a) held firm: what was measured in the first blood draw was, within analytical noise, what was measured years later.

But the small minority who did cross the 10-milligram threshold was not random, and this is where the study earns its clinical relevance. Using multivariable logistic regression, the team identified five independent predictors of a substantial Lp(a) rise: a higher baseline Lp(a) concentration, initiation of statin therapy between measurements, a diagnosis of diabetes mellitus, female sex, and higher triglyceride levels. Each of these factors points to a different biological thread, and together they sketch a picture of Lp(a) as a biomarker that, while genetically anchored, can be nudged by metabolic state, medication and perhaps hormonal influences.

The statin finding is likely to draw the most attention, and the most debate. Statins are the workhorse of cardiovascular prevention, yet their relationship with Lp(a) has been contentious for years, with some trials reporting modest increases in the particle among treated patients. The new cohort cannot disentangle whether statin-associated Lp(a) elevation reflects a direct pharmacological effect, a marker of worsening underlying atherosclerosis that prompted statin prescription, or some combination of both, and the authors are careful not to overinterpret the association. What it does suggest is that clinicians who start a patient on a statin and later observe a rising Lp(a) should not automatically assume the measurement is erroneous or that the drug is to blame without considering the broader clinical context.

The diabetes and triglyceride associations are equally intriguing from a mechanistic standpoint. Diabetes is known to influence several apolipoprotein-containing particles, and insulin resistance reshapes hepatic lipid handling in ways that could plausibly alter the assembly or clearance of Lp(a), which is produced almost exclusively by the liver. Higher triglycerides, a hallmark of metabolic syndrome, may similarly mark a hepatic environment in which Lp(a) production or catabolism shifts. The female sex signal, meanwhile, echoes prior observations that Lp(a) concentrations can rise after menopause, hinting at estrogen-related regulation, although the relatively young cohort, with a mean age of just over 42, means the study captured only the early edge of that transition.

For a field racing toward Lp(a)-lowering therapies, these longitudinal data arrive at a propitious moment. RNA-targeted drugs such as pelacarsen, olpasiran and lepodisiran are in late-stage trials and promise, for the first time, to suppress Lp(a) by 80 percent or more. Trial designers and clinicians alike have assumed that a single baseline measurement suffices to identify candidates and to judge treatment response. The new study broadly supports that assumption, since 97 percent of participants remained below the meaningful-change threshold, but it also flags the minority in whom a second measurement could change the risk calculus. The authors conclude that repeat Lp(a) testing may be warranted in selected high-risk individuals, particularly those with elevated baseline values, new diabetes, or newly initiated statin therapy, to sharpen cardiovascular risk stratification.

The study also fills an important geographic gap. Most longitudinal Lp(a) data come from European and North American cohorts, where median concentrations and LPA isoform distributions differ substantially from those in East Asian populations. The Taiwanese cohort’s median baseline value of 9.3 milligrams per deciliter sits well below the roughly 30 to 50 milligrams per deciliter often reported in populations of European descent, a disparity rooted in the frequency of small apolipoprotein(a) isoforms. Demonstrating that Lp(a) stability holds in an Asian population strengthens the case that lifetime genetic determination of this biomarker is a universal feature of human biology, not an artifact of any one ancestry.

Caveats remain, as they do with any retrospective database study. The cohort was predominantly male and middle-aged, the assay methodology was consistent within the health system but may not translate directly to other platforms, and unmeasured factors such as kidney function, thyroid status and inflammatory disease, all of which are known to modulate Lp(a), could not be fully adjusted. The work was funded by Novartis Pharmaceuticals, though the funder had no role in data acquisition, analysis or interpretation, and the authors declare no competing interests. Even with these limitations, the message is clear and reassuring in equal measure: for most people, one well-timed Lp(a) measurement tells you nearly everything you need to know, but for a definable minority, the story written in their genes can still acquire new chapters, and a repeat blood test may be the only way to read them.

Subject of Research: Long-term variability and clinical determinants of lipoprotein(a) concentrations

Article Title: Longitudinal patterns and determinants of lipoprotein(a) variability: a 15-year multi-center study

Article References: Tsai, M.-L., Chen, C.-C., Hsieh, M.-J., Chang, C.-Y., Chen, S.-W., Chen, T.-H., Chu, P.-H., Hsieh, I.-C., Hung, K.-C., Wen, M.-S., & Chen, D.-Y. (2026). Longitudinal patterns and determinants of lipoprotein(a) variability: a 15-year multi-center study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02631-1

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02631-1

Keywords: lipoprotein(a), cardiovascular risk, statins, diabetes mellitus, triglycerides, biomarkers, risk stratification, longitudinal cohort study, dyslipidemia, Taiwan, LDL cholesterol, genetic risk factors